Compare
AbbVie vs Amgen (ABBV vs AMGN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Amgen (AMGN) +43.9%; so far this year the figures are +27.5% and +40.7%.
AbbVie is the larger company by market value, about 2.1 times the size of Amgen.
On trailing earnings, ABBV trades at 50.1 times and AMGN at 26.7 times.
Revenue grew +10.7% at ABBV and +8.2% at AMGN over the last year.
ABBV yields 2.38%. AMGN yields 2.16%.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | AMGN | |
|---|---|---|
| Price | $291.31 | $460.42 |
| 1-day | +1.07% | +0.03% |
| YTD | +27.49% | +40.67% |
| 1 year | +34.39% | +43.94% |
| 3 years | +104.47% | +76.51% |
| Market cap | $514.9B | $249.1B |
| P/E | 50.1 | 26.7 |
| P/S | 7.80 | 6.40 |
| P/B | — | 17.35 |
| Revenue growth | +10.70% | +8.20% |
| EPS growth | +340.20% | +33.30% |
| Gross margin % | 73.7 | 70.9 |
| Net margin % | 15.7 | 24.1 |
| ROE % | — | 65.4 |
| Debt / equity | — | 3.76 |
| FCF yield % | 3.7 | 3.8 |
| Dividend yield % | 2.38 | 2.16 |
| Beta | -0.03 | 0.50 |
| RSI (14) | 59.7 | 60.5 |
| Technical rating |